Allogene Therapeutics (ALLO) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 21.1% versus a gain of 6.5%. Over five years, FENC leads with a +13.9% price change compared with -91.7% for ALLO. Allogene Therapeutics is the larger company by market cap ($452.6 million vs $350.0 million), about 1.3 times the size, while Fennec Pharmaceuticals is growing revenue faster (-6.1% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | FENC |
|---|---|---|
| Share price | $1.31 | $9.98 |
| Market cap | $452.59M | $349.97M |
| 1-day change | -2.24% | -3.57% |
| YTD return | -4.38% | +29.61% |
| 1-year return | +6.50% | +21.12% |
| 5-year return | -91.72% | +13.93% |
| Forward P/E | — | 10.53 |
| EPS (TTM) | $-0.66 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $44.64M |
| Revenue growth (YoY) | -100.00% | -6.09% |
| Net income (latest FY) | $-190.89M | $-9.74M |
| Operating margin | — | -14.07% |
| Net margin | — | -21.82% |
| 52-week high | $4.46 | $13.25 |
| 52-week low | $1.04 | $5.65 |
| Distance from 52-week high | -70.63% | -24.68% |
| Analyst consensus | none | none |
| Avg. price target upside | +587.02% | +77.05% |
| Average volume | 5.66M | 188.89K |
| Shares outstanding | 345.49M | 35.07M |
| Employees | 150 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed ALLO by 14.6 percentage points over the past year.
- Fennec Pharmaceuticals grew revenue faster in its latest fiscal year (-6.09% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Healthcare · Biotechnology · 150 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Healthcare · Biotechnology · 35 employees
ALLO vs FENC FAQ
Which is bigger, Allogene Therapeutics or Fennec Pharmaceuticals?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $452.59M compared with $349.97M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, ALLO or FENC?
FENC returned +21.12% over the past 12 months, compared with +6.50% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.